The efficacy and stem cell toxicity of cladribine and rituximab in the treatment of patients with chronic lymphocytic leukemia: are all purine analogs created equal?
Hematology Unit, Bnai-Zion Medical Center, Haifa, Israel.
Tamar
T
Tadmor
Aaron
A
Polliack
Constantine S
CS
Tam
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017338:Cladribine / Q000008:administration & dosage*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology; D011687:Purines / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D011687:Purines; D017338:Cladribine; D000069283:Rituximab; C030985:purine